Genezen, a best-in-class gene therapy CDMO, has announced an agreement to acquire uniQure’s (Nasdaq: QURE) commercial gene therapy operations in Lexington, MA, bringing a strategic manufacturing facility and a world-class team of employees to the company. Located just outside of Boston, the Lexington site is a commercially-licensed viral vector facility, enabling Genezen to support customers from preclinical development programs through late-phase and commercial manufacturing.
Read the full article: Genezen to Acquire uniQure’s Commercial Gene Therapy Manufacturing Operations in Lexington, MA //
Source: https://www.prnewswire.com/news-releases/genezen-to-acquire-uniqures-commercial-gene-therapy-manufacturing-operations-in-lexington-ma-302186384.html